- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04816799
Efficacy of START (Startle Rehabilitation Therapy) in the Treatment Stroke-induced Aphasia/Apraxia (START)
February 19, 2022 updated by: Claire Honeycutt, Arizona State University
A stratified, parallel-group, double-blind, randomized controlled trial of remotely delivered START treatment to individuals with severe-to-moderate stroke (with recruitment focused on individuals with low SES) will be conducted.
Subjects and assessors will be blinded to the condition making the experiment double blind.
Specifically, subjects will be told that we are exploring a new therapy that using different sounds to improve therapy.
Parallel group design will ensure that subjects in the Control group are unaware that their "sounds" are softer than the START group.
Trainers may become aware that a loud sound is present thus a unique Assessor will evaluate clinical performance before and after training making the study double-blind.
Fifty-four subjects will undergo baseline testing in the laboratory to establish their capacity for functional and expressive speech as well as their self-reported health-related quality of life (power analysis below).
Next, subjects will participate in a high-frequency, word-picture verification/ auditory-repetition treatment, 2 hr/day for 5 consecutive days focusing on expression of words of functional significance (e.g., water, fall).
Subjects will either receive training with START or without (Control).
Subjects will be re-tested immediately following training as well as one-month post to assess retention.
Aim 1 will evaluate capacity of START to enhance SLT outcomes by assessing the % change in clinical assessment of functional and expressive speech.
Our preliminary data points to a robust response [details].
Aim 2 will focus on the capacity of these changes to 1) be retained and 2) impact subject's reported quality of life.
NOTE: While we are planning in-person baseline, end, and retention testing, in response to COVID, we have established remote clinical screening using peer-reviewed validated techniques for WAB and ABA-2 (see Alternative Solutions).
All preliminary data collected for this proposal were collected remotely via no-contact protocols.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
54
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Claire F Honeycutt, PhD
- Phone Number: 4809658453
- Email: claire.honeycutt@asu.edu
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85287
- Recruiting
- Arizona State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years old
- Native English Speakers
- Capacity to provide informed consent
- Right-handed
- Corrected to normal vision
- Left hemisphere cerebral stroke at least 6 months prior to testing
- Presence of severe-to-moderate, non-fluent aphasia, i.e. Aphasia Quotients of 0-50 on the Western Aphasia Battery-Revised (PsychCorp, 2007)
- Corrected pure tone threshold (octave frequencies 250- 4000 Hz) norms for their age and gender41,42 NOTE: Audiometry data will be collected for all participants by lab personnel trained by an audiologist in a sound-attenuated booth. Based on our ongoing aphasia studies, we expect that ~30% of participants will use hearing aids; we will not exclude these individuals but rather include hearing aid use as a covariate in analyses.
Exclusion Criteria:
- Severe concurrent uncontrolled medical problems (e.g. cardiorespiratory impairment).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: START
START (startle adjuvant rehabilitation therapy) will be applied.
|
Exposure to loud acoustic stimulus during training of motor task (in this case speech).
|
NO_INTERVENTION: Control
Subjects will train but without START
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Western Aphasia Battery
Time Frame: end of training
|
(WAB) will be administered to determine aphasia severity via its aphasia quotient, as well as aphasia type.
Severe non-fluent aphasia will be defined as an aphasia quotient < 50 and a classification of Broca's, global, or transcortical motor aphasia.
|
end of training
|
Western Aphasia Battery Retention
Time Frame: one month post
|
(WAB) will be administered to determine aphasia severity via its aphasia quotient, as well as aphasia type.
Severe non-fluent aphasia will be defined as an aphasia quotient < 50 and a classification of Broca's, global, or transcortical motor aphasia.
|
one month post
|
Apraxia Battery for adults
Time Frame: end of training
|
(ABA-2) will be collected to identify presence and severity of apraxia of speech (AOS) via its six subtests: diadochokinetic rate, increasing word length, limb and oral apraxia, and latency and utterance for polysyllabic words, repeated trials, and inventory of articulation characteristics.
|
end of training
|
Apraxia Battery for adults Retention
Time Frame: one-month post
|
(ABA-2) will be collected to identify presence and severity of apraxia of speech (AOS) via its six subtests: diadochokinetic rate, increasing word length, limb and oral apraxia, and latency and utterance for polysyllabic words, repeated trials, and inventory of articulation characteristics.
|
one-month post
|
Stroke Impact Scale
Time Frame: Baseline, end of training, one-month post
|
(SIS) is a self-report scale of disability and health-related quality of life.
We will use the subdomains of Communication, ADL/LDL, Life participation, Quality of life, Social Relationships, Depression.
|
Baseline, end of training, one-month post
|
Stroke Impact Scale Retention
Time Frame: one-month post
|
(SIS) is a self-report scale of disability and health-related quality of life.
We will use the subdomains of Communication, ADL/LDL, Life participation, Quality of life, Social Relationships, Depression.
|
one-month post
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 22, 2020
Primary Completion (ANTICIPATED)
March 1, 2022
Study Completion (ANTICIPATED)
August 1, 2022
Study Registration Dates
First Submitted
March 23, 2021
First Submitted That Met QC Criteria
March 24, 2021
First Posted (ACTUAL)
March 25, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 22, 2022
Last Update Submitted That Met QC Criteria
February 19, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Psychomotor Disorders
- Language Disorders
- Communication Disorders
- Speech Disorders
- Stroke
- Aphasia
- Apraxias
Other Study ID Numbers
- STUDY00005229
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Startle Adjuvant Rehabilitation Therapy (START)
-
Arizona State UniversityRecruiting
-
Arizona State UniversityRecruiting
-
University of Southern CaliforniaRecruiting
-
Tao OUYANGActive, not recruiting
-
Stanford UniversityIowa State University; Pure Edge Inc.; Ponce Health Sciences UniversityRecruitingStress | Post Traumatic Stress Disorder | Burn Out | Mental Health Issue | Complex Posttraumatic Stress DisorderUnited States, Puerto Rico
-
The Central and Eastern European Gynecologic Oncology...RecruitingCervical CancerCzechia
-
PT. Prodia Stem Cell IndonesiaRecruitingNasopharyngeal CancerIndonesia
-
Asan Medical CenterUnknown
-
Medical Research CouncilCompletedHead and Neck Cancer | Non-melanomatous Skin CancerUnited Kingdom
-
Far Eastern Memorial HospitalCompletedHigh-risk Endometrial CancerTaiwan